Inclusion Criteria:~1. Males or females ≥55 years of age; female must be post-menopausal or must agree to
comply with contraception requirements. Males should also abide by contraceptive requirements when the partner
is a woman of childbearing potential. Acceptable methods of contraception include: combined (estrogen and
progestogen containing) hormonal contraception associated with inhibition of ovulation, which may be oral,
intravaginal, or transdermal; progestogen-only hormonal contraception associated with inhibition of ovulation,
which may be oral, injectable, or implantable; intrauterine device or intrauterine hormone-releasing system;
vasectomy of a female subject's male partner (with medical assessment and confirmation of vasectomy surgical
success); bilateral tubal occlusion~2. Diagnostic and Statistical Manual of Mental Disorders-5 (DSM 5) criteria
for Major Neurocognitive Disorder due to possible AD. Patients with Major Neurocognitive Disorder due to
multiple etiologies (AD and vascular) will be included~3. sMMSE ≤24~4. Presence of clinically significant
agitation based on the IPA definition at both screening and baseline~5. If treated with cognitive-enhancing
medications (cholinesterase inhibitors and/or memantine), dosage must be stable for at least 3 months prior to
study randomization~6. Availability of a primary caregiver to accompany the participant to study visits and to
participate in the study. The primary caregiver must be sufficiently proficient in English to complete the
required study assessments, as per investigator judgement and should spend at least 10 hours a week with the
participant~7. Willing and able to provide informed consent and/or have a Substitute Decision Maker (SDM)
provide informed consent on behalf of the participant~
